The future of drug discovery is at Envisagenics
We use Artificial Intelligence and Machine Learning to unlock the therapeutic potential of RNA.
Our platform leverages RNA sequencing data and AI/ML algorithms to identify, test and validate drug targets with greater speed and precision than traditional methods.
Traditional methods to detect RNA splicing variation have been limited – Envisagenics’ SpliceCore® platform is able to scale the discovery of splicing-derived drug targets.
SpliceCore® not only identifies new targets for RNA therapeutics but also explains the mechanism by which the antisense drugs regulate the splicing event, leading to more transparent and verifiable AI/ML predictions.
SpliceIOTM, the immunotherapeutic branch of SpliceCore®, identifies tumor specific neoepitopes targetable with a variety of antibody-based modalities.
larger search space for target discovery with SpliceCore’s exon-centric approach
experimental validation rate for SpliceCore-discovered targets
drug target candidates derived from disease-specific splicing events